Results from a pivotal study on oral semaglutide at a 25 mg dose for adults with overweight or obesity were published on January 1, 2025, in the New England Journal of Medicine. This publication details findings from the OASIS 4 research study, which investigated the efficacy of once-daily semaglutide tablets.
Background
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist available in various formulations, including oral tablets. It is used for the management of type 2 diabetes and, in higher doses, for chronic weight management. The OASIS 4 study specifically explored the efficacy of an oral formulation of semaglutide in adults with overweight or obesity.
Trial design
The OASIS 4 research study was designed to evaluate how well semaglutide tablets taken once daily work in people who have a body weight above the healthy range. The specific dose investigated in this publication was 25 mg, administered to adults with overweight or obesity.
What this means
The publication of these pivotal results for oral semaglutide 25 mg offers new data for clinicians treating adults with overweight or obesity. This information contributes to the understanding of the potential role and efficacy of higher-dose oral semaglutide in chronic weight management, providing a basis for informed treatment decisions.
Source
The information for this article is based on a pivotal publication in the New England Journal of Medicine, indexed on PubMed on January 1, 2025. The article is titled 'Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.' and can be accessed via pubmed.ncbi.nlm.nih.gov.